Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread and cannot be removed by surgery.
- Your tumor is not MSI-high or dMMR (a specific genetic type).
- You have already tried at least one type of chemotherapy for your metastatic cancer.
- You are able to provide a tumor tissue sample (from a past biopsy or a new one) for testing.
- Your kidney, liver, and blood cell counts are working well enough (checked by standard lab tests).
- You are willing to use highly effective birth control during and for 3 months after treatment (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This trial tests a new drug (HRS-2189) combined with two other medications (Adebrelimab and BP102) for people whose colorectal cancer has spread. It aims to see if this combination can help control the cancer.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of targeted radiation therapy, an immune-boosting drug, and two chemotherapy drugs for colorectal cancer that has spread or come back after two rounds of prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.